Godavari Drugs

Which are the latest news on Godavari Drugs?

Why is Godavari Drugs Ltd falling/rising?

As of 05-Sep, Godavari Drugs Ltd's stock price is rising, currently at 106.01, with a 7.22% increase. This upward trend is supported by strong investor interest, significant gains over various time frames, and increased trading volume, despite some underlying concerns regarding long-term fundamentals.

As of 05-Sep, Godavari Drugs Ltd's stock price is rising, currently at 106.01, reflecting a change of 7.14 (7.22%) upwards. This increase can be attributed to several factors. The stock has outperformed its sector by 8.77% today and has been on a consecutive gain streak for the last two days, accumulating a total return of 10.64% during this period. Additionally, the stock reached an intraday high of Rs 109.4, indicating strong investor interest.<BR><BR>The stock's performance over various time frames also supports its rising trend. Over the past week, it has increased by 6.01%, while in the last month, it has gained 3.02%. Year-to-date, the stock has shown a remarkable increase of 37.98%, significantly outperforming the benchmark Sensex, which has declined by 10.21% during the same period. Furthermore, the stock has generated a return of 24.84% over the past year, which is substantially higher than the market average return of 1.51%.<BR><BR>Investor participation has also risen, with delivery volume on September 3 increasing by 1177.96% compared to the 5-day average, indicating heightened interest and confidence among investors. The stock is trading at a discount compared to its peers' average historical valuations, which may attract more buyers.<BR><BR>However, it is important to note that there are underlying concerns, such as weak long-term fundamental strength and a high Debt to EBITDA ratio, which could affect future performance. Despite these concerns, the current data reflects a strong upward movement in the stock price of Godavari Drugs Ltd.

Who are in the management team of Godavari Drugs?

The management team of Godavari Drugs includes Mukund Kakani (Managing Director), Mohit Jaju (Whole Time Director & CFO), and several Non-Executive Directors, including Ghanshyam Jaju (Chairman) and S A Hussain. They are responsible for the company's governance and strategic direction.

The management team of Godavari Drugs includes the following key members:<BR><BR>1. **Mukund Kakani** - Managing Director<BR>2. **S A Hussain** - Non-Executive & Independent Director<BR>3. **Mohit Jaju** - Whole Time Director & CFO<BR>4. **Ramesh Babu Telugu** - Non-Executive & Independent Director<BR>5. **Vimala B Madon** - Non-Executive & Independent Director<BR>6. **Ghanshyam Jaju** - Chairman (Non-Executive)<BR>7. **Mahindra Uday Bhalerao** - Non-Executive Director<BR>8. **Venkatesh Achanta** - Company Secretary & Compliance Officer<BR><BR>This team plays a crucial role in the governance and strategic direction of the company.

What does Godavari Drugs do?

Godavari Drugs Ltd manufactures Active Pharmaceutical Ingredients (API) and drug intermediates in the Pharmaceuticals & Biotechnology industry. As of June 2026, it reported net sales of 28 Cr and a net profit of 1 Cr, with a market cap of INR 106 Cr.

Overview: <BR>Godavari Drugs Ltd is engaged in the manufacture of Active Pharmaceutical Ingredients (API) and drug intermediates, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.<BR><BR>History: <BR>The company was incorporated in an unspecified year and has maintained its status as a manufacturer of pharmaceuticals. The latest quarterly results reported are for June 2026, showing net sales and profit figures.<BR><BR>Financial Snapshot: <BR>- Net Sales: 28 Cr (Quarterly Results - Jun 2026) <BR>- Net Profit: 1 Cr (Quarterly Results - Jun 2026) <BR>- Market-cap: INR 106 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>- P/E: 27.00 <BR>- Industry P/E: 37 <BR>- Dividend Yield: 0.00% <BR>- Debt Equity: 0.88 <BR>- Return on Equity: 5.52% <BR>- Price to Book: 1.55 <BR><BR>Contact Details: <BR>Address: Mayfair 1-8-303-34, Sardar Patel Road Secunderabad Andhra Pradesh : 500003 <BR>Tel: 91-40-27849700/27844557 <BR>Email: info@godavaridrugs.com <BR>Website: http://www.godavaridrugs.com

Who are the peers of the Godavari Drugs?

Godavari Drugs' peers include Krebs Biochem, Makers Labs, Tyche Industries, Pharmaids Pharma, Concord Drugs, Veerhealth Care, Denis Chem Lab, Vaishali Pharma, and Sotac Pharma. In terms of performance, Makers Labs leads with a 1-year return of 25.01%, while Godavari Drugs has a return of 17.96%.

Peers: The peers of Godavari Drugs are Krebs Biochem, Makers Labs., Tyche Industries, Pharmaids Pharma, Concord Drugs, Veerhealth Care, Denis Chem Lab, Vaishali Pharma, and Sotac Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Denis Chem Lab, while Average management risk is found at Tyche Industries and Godavari Drugs, and the rest have Below Average management risk. Good growth is noted at Veerhealth Care, while Average growth is found at Pharmaids Pharma and Sotac Pharma, and the rest have Below Average growth. Excellent capital structure is seen at Tyche Industries and Denis Chem Lab, while Below Average capital structure is found at Makers Labs., Pharmaids Pharma, Godavari Drugs, Concord Drugs, Vaishali Pharma, and Sotac Pharma, and the rest have Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Makers Labs. at 25.01%, while Pharmaids Pharma has the lowest at -46.61%. Godavari Drugs has a 1-year return of 17.96%, which is higher than Pharmaids Pharma but lower than Makers Labs. Additionally, the six-month return is negative for Krebs Biochem, Tyche Industries, Pharmaids Pharma, Denis Chem Lab, and Vaishali Pharma.

How big is Godavari Drugs?

As of 31st August, Godavari Drugs Ltd has a market capitalization of 106.00 Cr, with recent net sales of 109.95 Cr and a net profit of 4.16 Cr. The balance sheet for March 2025 shows shareholder's funds of 43.35 Cr and total assets of 143.08 Cr.

As of 31st August, Godavari Drugs Ltd has a market capitalization of 106.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Godavari Drugs reported Net Sales of 109.95 Cr and a Net Profit of 4.16 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, showing Shareholder's Funds of 43.35 Cr and Total Assets of 143.08 Cr.

Should I buy, sell or hold Godavari Drugs Ltd?

When is the next results date for Godavari Drugs Ltd?

The next results date for Godavari Drugs Ltd is 14 August 2026.

The next results date for Godavari Drugs Ltd is scheduled for 14 August 2026.

Are Godavari Drugs Ltd latest results good or bad?

Godavari Drugs Ltd's latest Q4 FY26 results show strong short-term growth with a 69.66% increase in net profit and a 49.50% rise in revenue, but concerns arise from a declining operating margin and low return on equity, indicating potential long-term challenges. Overall, the results are good short-term but raise questions about sustainability.

Godavari Drugs Ltd's latest results for Q4 FY26 show a mixed picture. On the positive side, the company achieved a net profit of ₹1.29 crores, which is a significant increase of 69.66% compared to the previous quarter. Additionally, revenue grew impressively by 49.50% quarter-on-quarter, reaching ₹33.16 crores, marking the highest quarterly sales in the company's history.<BR><BR>However, there are notable concerns as well. The operating margin decreased to 8.84%, down from 11.14% in the previous quarter, indicating that the revenue growth came at the expense of operational efficiency. Furthermore, the return on equity (ROE) stands at a modest 8.82%, which is below industry standards, reflecting challenges in capital efficiency.<BR><BR>Overall, while the quarterly performance shows strong short-term momentum, the company's long-term fundamentals remain weak, with a negative five-year sales CAGR of 2.92% and ongoing operational challenges. Thus, the results can be seen as good in the short term but concerning in the context of long-term sustainability. Investors should weigh these factors carefully.

How has been the historical performance of Godavari Drugs?

Godavari Drugs has shown a declining trend in net sales and profits over the past two years, with net sales dropping from 159.62 Cr in Mar'23 to 113.35 Cr in Mar'25, while total assets and liabilities have increased, indicating rising debt levels. Operating profit margins improved slightly, but overall financial performance reflects challenges in the market.

Answer:<BR>The historical performance of Godavari Drugs shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Godavari Drugs reported net sales of 113.35 Cr in Mar'25, a decline from 156.71 Cr in Mar'24 and 159.62 Cr in Mar'23, indicating a downward trend in revenue. The total operating income followed a similar pattern, decreasing from 156.71 Cr in Mar'24 to 113.35 Cr in Mar'25. Raw material costs also decreased to 85.24 Cr in Mar'25 from 121.95 Cr in Mar'24, while total expenditure fell to 101.52 Cr in Mar'25 from 143.41 Cr in Mar'24. Operating profit, excluding other income, was 11.83 Cr in Mar'25, slightly lower than 13.30 Cr in Mar'24, but the operating profit margin improved to 10.44%. Profit before tax decreased to 5.63 Cr in Mar'25 from 6.92 Cr in Mar'24, and profit after tax also fell to 4.38 Cr from 5.55 Cr. The company's total assets increased to 143.08 Cr in Mar'25 from 134.75 Cr in Mar'24, while total liabilities rose to 143.08 Cr from 134.75 Cr, indicating a growing debt level. Cash flow from operating activities decreased to 11.00 Cr in Mar'25 from 18.00 Cr in Mar'24, while cash flow from investing activities worsened to -19.00 Cr. Overall, Godavari Drugs has experienced a decline in sales and profits, alongside an increase in total assets and liabilities, reflecting a challenging financial environment.

Is Godavari Drugs overvalued or undervalued?

As of September 18, 2025, Godavari Drugs is considered very attractive and undervalued, with a PE ratio of 16.95, an EV to EBITDA of 10.77, and a ROCE of 11.66%, significantly lower than peers like Sun Pharma and Divi's Lab, while also showing strong long-term growth potential despite recent underperformance against the Sensex.

As of 18 September 2025, the valuation grade for Godavari Drugs has moved from attractive to very attractive, indicating a significant improvement in its perceived value. The company is currently considered undervalued. Key ratios include a PE ratio of 16.95, an EV to EBITDA of 10.77, and a ROCE of 11.66%. <BR><BR>In comparison to its peers, Godavari Drugs stands out with a much lower PE ratio than Sun Pharma (34.46) and Divi's Lab (70.44), both of which are classified as expensive. Additionally, Godavari's PEG ratio is notably at 0.00, suggesting strong growth potential relative to its price. While the stock has underperformed the Sensex over the past year, its recent 5-year return of 136.84% compared to the Sensex's 113.70% highlights its long-term value proposition.

What is the technical trend for Godavari Drugs?

As of May 30, 2025, Godavari Drugs shows a mildly bearish trend, influenced by daily moving averages and monthly indicators, despite mixed signals from weekly MACD and KST.

As of 30 May 2025, the technical trend for Godavari Drugs has changed from sideways to mildly bearish. The daily moving averages indicate a mildly bearish stance, while the weekly MACD and KST are mildly bullish, creating a mixed signal. The monthly MACD and Bollinger Bands are bearish, which adds to the overall bearish sentiment. The RSI shows no signal in both weekly and monthly time frames, indicating a lack of momentum. Overall, the current technical stance is mildly bearish, driven primarily by the daily moving averages and the monthly indicators.

Who are the top shareholders of the Godavari Drugs?

The top shareholders of Godavari Drugs include promoter Sushma Kakani with 15.34%, Highcrestt Global Company Ltd as the largest public shareholder at 2.66%, and individual investors holding a combined 39.93%. There are currently no mutual funds or foreign institutional investors in the company.

The top shareholders of Godavari Drugs include the promoters, who hold the majority of the shares. The promoter with the highest holding is Sushma Kakani, with a stake of 15.34%. Additionally, Highcrestt Global Company Ltd is the highest public shareholder, owning 2.66% of the company. Individual investors collectively hold 39.93% of the shares. Notably, there are currently no mutual funds or foreign institutional investors (FIIs) holding shares in the company.

Has Godavari Drugs declared dividend?

No Dividend History Available